Promising improvements in blood glucose control were obtained with the acylated unimolecular dual GIP/GLP-1 agonist RG7697/NNC0090-2746 in healthy [327] and T2D patients [328] and significant reductions in body weight were achieved but the magnitude was possibly similar to liraglutide treatment alone [329]. This evidence concerns the gene GIP and type 2 diabetes mellitus.